Abstract
Converging data from epidemiological and biological research implicate insulin-like growth factor (IGF) physiology in the regulation of prostate epithelial cell proliferation and in the pathophysiology of prostate cancer. This review (1)outlines elements of IGF physiology, (2) reviews recent evidence that circulating IGF-I level is related to risk of prostate cancer, (3) provides a hypothesis concerning the biological basis for the relationship between IGF-1 level and risk of prostate cancer, (4) discusses IGF-I physiology in the context of neoplastic progression of prostate cancer, and (5) discusses clinical implications of these lines of research with respect to prevention and treatment.
Similar content being viewed by others
References
Jones JI, Clemmons DR: Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev 16: 3-34, 1995
Thissen JP, Ketelslegers JM, Underwood LE: Nutritional regulation of the insulin-like orowth factors. Endo Rev 15: 80-101, 1994
Juul A, Bang P, Hertel N, Main K, Dalgaard P, Jorgensen K, Muller J, Hall K, Skakkebaek NE: Serum insulin-like growth factor I in 1030 healthy children, adolescents, and adults: relation to age, sex, stage of puberty, testicular size, and body mass index. J Clin Endocrinol Metab 78: 744-752, 1994
Pollak M, Costantino J, Polychronakos C, Blauer S, Guyda H, Redmond C, Fisher B, Margolese R: Effect of tamoxifen on serum insulin-like growth factor I levels in stage I breast cancer patients. JNCI 82:1693-1697, 1990
Huynh HT, Tetenes E, Wallace L, Pollak M: In vivoinhibition of insulin-like growth factor-I gene expression by tamoxifen. Cancer Res. 53: 1727-1730, 1993
Huynh HT, Yang XF, Pollak M: Estradiol and antiestrogens regulate a growth inhibitory insulin-like growth factor binding protein 3 autocrine loop in human breast cancer cells. J Biol Chem 271: 1016-1021, 1996
Kulik G, Weber MJ: Akt-dependent and independent survival signaling pathways utilized by insulin-like growth factor I. Mol Cell Biol 11: 6711-6718, 1998
Parrizas M, Saltiel AR, LeRoith D: Insulin-like growth factor 1 inhibits apoptosis using the phosphatidylinositol 3′-kinase and mitogen-activated protein kinase pathways. J Biol Chem 272: 154-161, 1997
LeRoith D, Werner H, Beitner-Johnson D, Roberts C: Molecular and cellular aspects of the insulin-like growth factor I receptor. Endocr Rev 16: 143-163, 1995
Yang XF, Beamer W, Huynh HT, Pollak M: Reduced growth of human breast cancer xenografts in hosts homozygous for the ‘lit’mutation. Cancer Res 56: 1509-1511, 1996
Cohen P, Peehl DM, Lamson G, Rosenfeld RG: Insulin-like growth factors (IGFs), IGF receptors, and IGF-binding proteins in primary cultures of prostate epithelial cells. J Clin Endocrinol Metab 73: 401-407, 1991
Cohen P, Peehl DM, Rosenfeld RG: The IGF axis in the prostate. Horm Metab Res 26: 81-84, 1994
Chan JM, Stampfer MK, Giovannucci E, Gann PH, Ma J, Wilkinson P, Hennekens CH, Pollak M: Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science 279: 563-566, 1998
Wolk A, Mantzoros CS, Andersson S-O, Bergstrom R, Signorello LB, Lagiou P, Adami H-O, Trichopoulos D: Insulin-like growth factor 1 and prostate cancer risk: a population-based, case-control study. JNCI 90: 911-915, 1998
Mantzoros CS, Tzonou A, Signorello LB, Stampfer M, Trichopoulos D, Adami HO: Insulin-like growth factor 1 in relation to prostate cancer and benign prostatic hyperplasia. Br J Cancer 76: 1115-1118, 1997
Juul A, Main K, Blum WF, Lindholm J, Ranke MB, Skakkebaek NE: The ratio between serum levels of Insulin-like growth factor (IGF)-1 and the IGF binding proteins (IGFBP)-1, 2 and 3 decreases with age in healthy adults and is increased in acromegalic patients. Clin Endocrinol 41: 85-93, 1994
Hankinson SE, Willett WC, Colditz GA, Hunter DJ, Michaud DS, Deroo B, Rosner B, Speizer FE, Pollak M: Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet 351: 1393-1396, 1998
Pollak M, Ma J, Giovannucci E, Platz EA, Majeed N, Tao Y, Chan J, Hennekens CH, Colditz GA, Speizer F, Willett W, Hankinson S, Stampfer MJ: Circulating levels of IGF-I and IGFBP-3 are related to risk of colorectal cancer. Submitted, 1998
Pollak M, JazmajiV, Jenkins D, Marcon N, Saibil F, Stern H, Baron D, Majeed N, Tao Y, McKeown-Eyssen GE: Relationship of colorectal cancer risk to serum insulin-like growth factor I and insulin-like growth factor binding protein 3. Submitted, 1998
Cohen SM Ellwein LB: Genetic Errors, Cell Proliferation, and Carcinogenesis. Cancer Res 51: 6493-6505, 1991
Cohen SM Ellwein LB: Cell proliferation in carcinogenesis. Science 249: 1007-1011, 1990
Preston-Martin S, Pike MC, Ross RK, Henderson BE: Epidemiologic evidence for the increased cell proliferation model of carcinogenesis. Environ Health Persp 101: 137-138, 1993
Butterworth BE, Goldsworthy TL: The role of cell proliferation in multistage carcinogenesis. PSEBM 198: 683-687, 1991
Cohen SM: Role of cell proliferation in regenerative and neoplastic disease. [Review] [20 refs]. Toxicol Let 82-83: 15-21, 1995
Rosen C, Pollak M: Circulating IGF-I: a new prospective for a new century. Trends in endocrinology and metabolism, (In press)
Rosen CJ, Kurland ES, Vereault D, Adler RA, Rackoff PJ, Craig WY, Witte S, Rogers J, Bilezikian JP: Association between serum insulin growth factor-I (IGF-I) and a simple sequence repeat in IGF-I gene: implications for genetic studies of bone mineral density. iJ Clin Endocrinol Metab 83: 2286-2290, 1998
Zhang L, Zhou W, Velculescu VE, Kern SE, Hruban RH, Hamilton SR, Vogelstein B, Kinzler KW: Gene expression profiles in normal and cancer cells. Science 276: 1268-1272, 1997
Cui H, Horon IL, Ohlsson R, Hamilton SR, Feinberg AP: Loss of imprinting in normal tissue of colorectal cancer patients with microsatellite instability. Nature Medicine 4: 1276-1280, 1998
Cohen P, Graves CB, Peehl DM, Kamarei M, Giudice LC, Rosenfeld RG: Prostate-specific antigen (PSA) is an Insulin-like growth factor binding protein-3 protease found in seminal plasma. J Clin Endo Met 75: 1046-1053, 1992
Nickerson T, Pollak M, Huynh H: Castration-induced apoptosis in the rat ventral prostate is associated with increased expression of genes encoding insulin-like growth factor binding proteins 2, 3, 4 and 5. Endocrinol 139: 807-810, 1998
Nickerson T, Pollak M: Bicalutamide (Casodex)-induced prostate regression involves increased expression of genes encoding insulin-like growth factor binding proteins. Submitted, 1998
Nickerson T, Huynh H: Vitamin D analogue EB1089-induced prostate regression is associated with increased gene expression of insulin-like growth factor binding proteins. J Endo, (In press)
Rozen F, Yang X, Huynh HT, Pollak M: Antiproliferative action of vitamin-D-related compounds and insulin-like growth factor binding protein 5 accumulation. J Natl Cancer Inst 89: 652-656, 1997
Pollak M, Schally AV: Mechanism of antineoplastic action of somatostatin analogues. Proc Soc Exp Bio Med 217: 143-152, 1998
http://cancernet.nci.nih.gov/cgi-bin/cancerphy show?fileDpro12541.html. 1998
http://cancernet.nci.nih.gov/cgi-bin/cancerphy show?fileDpro12166.html. 1998
Lamharzi N, Schally AV, Koppan M, Groot K: Growth hormone-releasing antagonist Mz-5-156 inhibits growth of DU-145 human androgen-independent prostate carcinoma in nude mice and suppresses the levels and mRNA expression of insulin-like growth factor II in tumours. Proc Natl Acad Sci USA 95: 8864-8868, 1998
Baserga R: The insulin-like growth factor I receptor: a key to tumor growth? Cancer Res 55: 249-252, 1995
Baserga R, Hongo A, Rubini M, Prisco M, Valentinis B: The IGF-I receptor in cell growth, transformation and apoptosis. Biochim Biophys Acta 1332: F105-F126, 1997
Baselga J, Norton L, Albanell J, Kim YM, Mendelsohn J: Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res 58: 2825-2831, 1998
Pegram MD, Lipton A, Hayes DF, Weber BL, Baselga JM, Tripathy D, Baly D, Baughman SA, Twaddell T, Glaspy JA, Slamon DJ: Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol 16: 2659-2671, 1998
Slamon DJ, Leyland-Jones B, Shak S et al.: Addition of Herceptin (humanized anti-HER2 antibody) to first-line chemotherapy for HER2 overexpressing metastatic breast cancer (HER2C=MBC) markedly increases anticancer activity: A randomized, mutlinational controlled phase III trial. Proc Am Soc Clin Oncology 17: 1998 (Abstract)
Barinaga M: Study suggests new way to gauge prostate cancer risk. Science 279: 475, 1998
Thompson IM, Coltman CAJ, Crowley J: Chemoprevention of prostate cancer: the Prostate Cancer Prevention Trial. Prostate 33: 217-221, 1997
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Pollak, M., Beamer, W. & Zhang, JC. Insulin-like Growth Factors and Prostate Cancer. Cancer Metastasis Rev 17, 383–390 (1998). https://doi.org/10.1023/A:1006154108619
Issue Date:
DOI: https://doi.org/10.1023/A:1006154108619